Most read For Subscribers Currencies Commodities Jse Indexes Brent Crude 41.98 (+0.17) Palladium 2204.00 (+0.07) All Share 54247.81 (+1.84) Financial 15 9588.13 (+0.19) Industrial 25 74229.70 (+3.26) Resource 10 53508.98 (+1.08) All JSE data delayed by at least 15 minutes Newsletters Business Briefing - weekly A deep dive into the big business story of the…
There is a realigning of fundamentals in terms of how individuals and companies see their roles; how artificial intelligence is used, and what that means for design.Prepare for the "never normal" likely to be the case over the next three years, says serial entrepreneur Mark Curtis.The coronavirus pandemic will enhance seven key trends. Forget about the…
The FDA has cleared the interleukin (IL)-23 inhibitor tildrakizumab (Ilumya) for the treatment of active psoriatic arthritis (PsA) in adults. Sun Pharma announced the approval on October 30. “As an IL-23 inhibitor administered exclusively by a healthcare provider, Ilumya is now an option for adults with active psoriatic arthritis who are unable to self-administer treatment
Millions of Medicare enrollees who buy stand-alone prescription drug plans will see their average monthly premiums rise by 50% in 2027, a new analysis finds. But enrollees can avoid the average increase — from $34 a month to $51 — by switching to lower-cost plans during the program’s open enrollment period, which runs through Dec.
You don't have permission to access "http://www.medpagetoday.com/washington-watch/washington-watch/123652" on this server. Reference #18.d494d817.1793332899.22e6a54f https://errors.edgesuite.net/18.d494d817.1793332899.22e6a54f